Biotech Restricted Cash: Reconcile the Runway Balance
Reconcile cash, restricted cash and the cash-flow ending balance in a dated SEC filing before using the liquidity amount in a biotech runway scenario.
Which cash balance belongs in a runway worksheet?
Do not automatically use a cash-flow statement's ending total as spendable liquidity. Read its label, reconcile it to the balance sheet and inspect the restriction note. A combined accounting total can contain cash that is held for a specified purpose rather than available for the spending scenario being modeled.
The SEC financial-statement guide distinguishes a balance-sheet snapshot from cash flows over a period. Keep both dates and definitions. The cash-runway worksheet supplies the broader funding method; this example addresses the narrower problem of choosing and reconciling its cash input.
Choose a company and prepare a question. Run it manually after confirming the question and reviewing the required credits.
Prepared research question
Which pipeline valuation assumptions remain unproven for a company I choose?
Traceable citations · Unknowns marked
A historical filing makes the difference visible
The original Editas Medicine 2025 Form 10-K contains the following reconciliation in its consolidated cash-flow statement, printed page 127. Its heading states amounts in thousands. These are balances at December 31, 2025, not current October 2026 balances.
| Reported line | December 31, 2025, USD thousands |
|---|---|
| Cash and cash equivalents, end of period | 146,645 |
| Restricted cash | 2,670 |
| Cash, cash equivalents and restricted cash, end of period | 149,315 |
The arithmetic is 146,645 + 2,670 = 149,315, in the reported units. The cash-flow total is not an additional pool to add to the cash-and-equivalents line.
Note 2, under “Cash, Cash Equivalents, and Restricted Cash,” describes collateral for office and laboratory facilities and a credit-card program. The note rounds restricted cash to $2.7 million; the reconciliation retains $2.670 million. Keep that precision difference rather than turning the rounded note into a conflicting $2.700 million table input.
The statement's footnote places restricted cash within restricted cash and other non-current assets. The larger balance-sheet asset category and the restricted-cash component are different fields; do not substitute the whole category for its component.
Identify amounts already represented elsewhere
The filing's fair-value note also reports money-market funds of 146,645 thousand in cash equivalents and 2,670 thousand in restricted cash, totaling 149,315 thousand of financial assets at that date. This is another presentation of the selected balances, not evidence of a second 149,315-thousand cash resource.
A useful ledger retains source section, period, units, component and total relationships. Check those relationships before adding amounts with similar names. A source-bound total should not be counted again merely because it appears in a cash-flow reconciliation and a fair-value table.
This example does not establish that every dollar in the cash-and-equivalents line is available for every future obligation. Any release conditions for restricted funds, other commitments and a current financing plan require their own evidence. Those inputs remain UNKNOWN here.
A positive cash change does not erase operating cash use
The same 2025 cash-flow statement reports, in thousands, operating cash use of 165,241, investing cash provided of 138,668 and financing cash provided of 40,470. With their signs preserved, −165,241 + 138,668 + 40,470 = 13,897, the reported increase in the combined cash measure.
The investing section includes maturities of marketable securities. Moving an investment into cash changes its presentation; it does not make the same investment value available twice. The financing section separately reports 42,848 thousand of net ATM equity proceeds. That historical receipt is distinct from unused offering capacity or a possible later sale.
Keep the operating-burn period beside the cash snapshot. An annual amount is not one quarter's burn, and an end-of-year balance is not evidence of today's resources. The SEC filing worksheet explains cumulative-period reconciliation; the ATM ledger separates capacity, proceeds and dilution.
Prepare the next research question without inventing a runway
For a selected company and date, reconcile the reported ending cash measure to its components, document restrictions, identify overlapping investment balances and separate operating use from investing and financing flows. Then bring in dated obligations and the next milestone's original evidence before estimating a funding gap.
The year-end snapshot, the report's March 9, 2026 signature date and our October 13 source capture are separate anchors. This draft has not established current Editas liquidity, a release date for collateral, a future spending rate or a current milestone. It therefore supplies no current-company runway or financing deadline.
Use the existing valuation-assumptions research task after selecting a company. The article supplies a reconciliation method; current business facts must come from the sources loaded for that research.
Get SEC Cash Runway & Dilution Risk Alerts
Track quarterly cash burn, S-3 shelf capacity, and runway-vs-catalyst mismatches grounded in SEC Form 10-Q/10-K filings.
Related Articles
Biotech ATM Offerings and the Form S-3 Baby Shelf Rule: Modeling Dilution
Calculate biotech share dilution under Form S-3 General Instruction I.B.6 Baby Shelf caps, Rule 415 ATM programs, 424B5 supplements, and pre-readout burn.
FDA Pre-Approval Inspections (PAI): Form 483 vs OAI and Warning Letters
Differentiate FDA Pre-Approval Inspection Form 483 observations, OAI classifications, and Warning Letters to audit CDMO manufacturing CRL risk in SEC filings.
FDA Post-CRL Resubmissions: Type A Meetings and Class 1 vs Class 2 Clocks
Model FDA post-CRL NDA and BLA resubmission timelines: Type A vs Type B meetings, 2-month Class 1 vs 6-month Class 2 PDUFA clocks, and SEC 8-K verification.